Market Alert: Trump’s Tariff Policy Pressures Healthcare Stocks

HITIQ Secures AU$250,000 Placement and New AU$1.4 Million Loan Facility to Advance Consumer Market Pivot.

Sep 29, 2025

HITIQ Limited (ASX: HIQ) has bolstered its capital position through an AU$250,000 placement and a new AU$1.4 million RDTI loan facility to support its consumer market expansion. The placement, issued at AU$0.022 per share, raised funds from a strategic investor and included one option for every two shares, exercisable at the same price and expiring in December 2028. The issue price reflects a 22.2% premium to the recent closing price and 7.7% above the 15-day VWAP, highlighting investor confidence.

In addition, HITIQ has entered into an AU$1.4 million loan agreement with No Bull Health Pty Ltd, associated with its major shareholder Harmil Angel Investments. An initial AU$480,000 has already been drawn, with shareholder approval to secure the loan against forecast R&D expenditure to be sought at the upcoming AGM. These funds will be directed towards accelerating HITIQ’s commercialisation of its concussion management technology and driving its consumer-focused growth strategy.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com